{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T05:16:14Z","timestamp":1788671774191,"version":"build-2803163510"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T00:00:00Z","timestamp":1746230400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["C45074\/A26553"],"award-info":[{"award-number":["C45074\/A26553"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","esmorwd.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Real World Data and Digital Oncology"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.esmorw.2025.100156","type":"journal-article","created":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T08:15:02Z","timestamp":1748938502000},"page":"100156","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Advanced risk signature analysis of inflammation markers in predicting prostate cancer using the Swedish Apolipoprotein-related MOrtality RISk (AMORIS) cohort"],"prefix":"10.1016","volume":"8","author":[{"given":"G.","family":"George","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Rowley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.C.C.","family":"Coolen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Santa Olalla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Hammar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Feychting","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.N.","family":"Karagiannis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Enting","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Van Hemelrijck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.esmorw.2025.100156_bib1","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1038\/nrc2090","article-title":"Inflammation in prostate carcinogenesis","volume":"7","author":"De Marzo","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.esmorw.2025.100156_bib2","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/978-3-0348-0837-8_7","article-title":"The role of inflammation in prostate cancer","volume":"816","author":"Sfanos","year":"2014","journal-title":"Adv Exp Med Biol"},{"issue":"5","key":"10.1016\/j.esmorw.2025.100156_bib3","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.ejca.2015.01.002","article-title":"The elevated C-reactive protein level is associated with poor prognosis in prostate cancer patients treated with radiotherapy","volume":"51","author":"Thurner","year":"2015","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1016\/j.esmorw.2025.100156_bib4","doi-asserted-by":"crossref","first-page":"467","DOI":"10.4103\/1008-682X.123686","article-title":"Prognostic role of C-reactive protein in prostate cancer: a systematic review and meta-analysis","volume":"16","author":"Liu","year":"2014","journal-title":"Asian J Androl"},{"issue":"12","key":"10.1016\/j.esmorw.2025.100156_bib5","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1002\/ijc.28313","article-title":"Prediagnostic circulating markers of inflammation and risk of prostate cancer","volume":"133","author":"Toriola","year":"2013","journal-title":"Int J Cancer"},{"issue":"6","key":"10.1016\/j.esmorw.2025.100156_bib6","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1002\/ijc.25773","article-title":"Risk of prostate cancer is not associated with levels of C-reactive protein and other commonly used markers of inflammation","volume":"129","author":"Van Hemelrijck","year":"2011","journal-title":"Int J Cancer"},{"issue":"11","key":"10.1016\/j.esmorw.2025.100156_bib7","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1002\/ijc.31256","article-title":"Serum inflammatory markers in relation to prostate cancer severity and death in the Swedish AMORIS study","volume":"142","author":"Arthur","year":"2018","journal-title":"Int J Cancer"},{"issue":"1","key":"10.1016\/j.esmorw.2025.100156_bib8","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1002\/cjp2.87","article-title":"Histological scoring of immune and stromal features in breast and axillary lymph nodes is prognostic for distant metastasis in lymph node-positive breast cancers","volume":"4","author":"Grigoriadis","year":"2018","journal-title":"J Pathol Clin Res"},{"issue":"7","key":"10.1016\/j.esmorw.2025.100156_bib9","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/j.ophtha.2020.11.024","article-title":"Genetic risk, lifestyle, and age-related macular degeneration in Europe: the EYE-RISK consortium","volume":"128","author":"Colijn","year":"2021","journal-title":"Ophthalmol"},{"issue":"37","key":"10.1016\/j.esmorw.2025.100156_bib10","doi-asserted-by":"crossref","DOI":"10.1088\/1751-8121\/aa812f","article-title":"Replica analysis of overfitting in regression models for time-to-event data","volume":"50","author":"Coolen","year":"2017","journal-title":"J Phys A Math Theor"},{"issue":"38","key":"10.1016\/j.esmorw.2025.100156_bib11","doi-asserted-by":"crossref","DOI":"10.1088\/1751-8121\/ab375c","article-title":"Analysis of overfitting in the regularized Cox model","volume":"52","author":"Sheikh","year":"2019","journal-title":"J Phys A Math Theor"},{"issue":"36","key":"10.1016\/j.esmorw.2025.100156_bib12","doi-asserted-by":"crossref","DOI":"10.1088\/1751-8121\/aba028","article-title":"Replica analysis of overfitting in generalized linear regression models","volume":"53","author":"Coolen","year":"2020","journal-title":"J Phys A Math Theor"},{"key":"10.1016\/j.esmorw.2025.100156_bib13","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.73288","article-title":"Predicting progression-free survival after systemic therapy in advanced head and neck cancer: Bayesian regression and model development","volume":"11","author":"Barber","year":"2022","journal-title":"Elife"},{"issue":"4","key":"10.1016\/j.esmorw.2025.100156_bib14","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1093\/ije\/dyw333","article-title":"Cohort profile: the AMORIS cohort","volume":"46","author":"Walldius","year":"2017","journal-title":"Int J Epidemiol"},{"issue":"1","key":"10.1016\/j.esmorw.2025.100156_bib15","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/s41392-023-01502-8","article-title":"Inflammation and aging: signaling pathways and intervention therapies","volume":"8","author":"Li","year":"2023","journal-title":"Signal Transduct Target Ther"},{"issue":"19","key":"10.1016\/j.esmorw.2025.100156_bib16","doi-asserted-by":"crossref","DOI":"10.3390\/ijms231911501","article-title":"Prognostic value of albumin to globulin ratio in non-metastatic and metastatic prostate cancer patients: a meta-analysis and systematic review","volume":"23","author":"Salciccia","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"2","key":"10.1016\/j.esmorw.2025.100156_bib17","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000041242","article-title":"Causal relationship between rheumatoid arthritis, systemic lupus erythematosus, ankylosing spondylitis and risk of prostate cancer: multivariable and bidirectional Mendelian-randomization analyses","volume":"104","author":"Ye","year":"2025","journal-title":"Medicine (Baltimore)"},{"issue":"4","key":"10.1016\/j.esmorw.2025.100156_bib18","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.cpt.2024.03.002","article-title":"Association between autoimmunity-related disorders and prostate cancer: a Mendelian randomization study","volume":"2","author":"Chen","year":"2024","journal-title":"Cancer Pathog Ther"},{"issue":"6","key":"10.1016\/j.esmorw.2025.100156_bib19","first-page":"420","article-title":"Autoimmune pancreatitis as a risk factor of pancreatic cancer","volume":"39","author":"Solil","year":"2024","journal-title":"Klin Onkol"},{"issue":"1","key":"10.1016\/j.esmorw.2025.100156_bib20","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1038\/s41467-022-29719-1","article-title":"TNF is a potential therapeutic target to suppress prostatic inflammation and hyperplasia in autoimmune disease","volume":"13","author":"Vickman","year":"2022","journal-title":"Nat Commun"},{"issue":"7","key":"10.1016\/j.esmorw.2025.100156_bib21","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1111\/j.1464-410X.2005.05447.x","article-title":"C-reactive protein is significantly associated with prostate-specific antigen and metastatic disease in prostate cancer","volume":"95","author":"Lehrer","year":"2005","journal-title":"BJU Int"},{"issue":"2","key":"10.1016\/j.esmorw.2025.100156_bib22","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/s41433-021-01759-9","article-title":"Risk of bias: why measure it, and how?","volume":"36","author":"Phillips","year":"2022","journal-title":"Eye"},{"issue":"6917","key":"10.1016\/j.esmorw.2025.100156_bib23","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/nature01322","article-title":"Inflammation and cancer","volume":"420","author":"Coussens","year":"2002","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.esmorw.2025.100156_bib24","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1038\/bjc.2015.355","article-title":"The impact of patient comorbidity on cancer stage at diagnosis","volume":"113","author":"Gurney","year":"2015","journal-title":"Br J Cancer"},{"issue":"6","key":"10.1016\/j.esmorw.2025.100156_bib25","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.trecan.2020.12.010","article-title":"How comorbidities shape cancer biology and survival","volume":"7","author":"Panigrahi","year":"2021","journal-title":"Trends Cancer"},{"issue":"27","key":"10.1016\/j.esmorw.2025.100156_bib26","doi-asserted-by":"crossref","first-page":"41758","DOI":"10.18632\/oncotarget.9676","article-title":"High serum haptoglobin level is associated with tumor progression and predicts poor prognosis in non-small cell lung cancer","volume":"7","author":"Lu","year":"2016","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.esmorw.2025.100156_bib27","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1111\/bju.13059","article-title":"Causes of death in men with localized prostate cancer: a nationwide, population-based study","volume":"117","author":"Van Hemelrijck","year":"2016","journal-title":"BJU Int"},{"issue":"13","key":"10.1016\/j.esmorw.2025.100156_bib28","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1002\/sim.7246","article-title":"A latent class model for competing risks","volume":"36","author":"Rowley","year":"2017","journal-title":"Stat Med"}],"container-title":["ESMO Real World Data and Digital Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949820125000451?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949820125000451?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T04:53:27Z","timestamp":1788670407000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2949820125000451"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":28,"alternative-id":["S2949820125000451"],"URL":"https:\/\/doi.org\/10.1016\/j.esmorw.2025.100156","relation":{},"ISSN":["2949-8201"],"issn-type":[{"value":"2949-8201","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advanced risk signature analysis of inflammation markers in predicting prostate cancer using the Swedish Apolipoprotein-related MOrtality RISk (AMORIS) cohort","name":"articletitle","label":"Article Title"},{"value":"ESMO Real World Data and Digital Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmorw.2025.100156","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100156"}}